- Di sistema
- This meeting will provide you with the latest insights in car t and reported clinical data, making it an invaluable opportunity to stay at the forefront of this rapidly evolving field. In addition, novel treatments based on anticancer rna-vaccination or on radioligands have been recently introduced in the clinical practice. Rationale, pro and contra and the identification of particular subset of patients who could actually benefit from these approaches will be discussed. Finally, in the meeting will be discussed how the progress in the molecular characterization of the tumor based on institutional tumor molecular boards might allow the identification of novel therapeutic targets.
As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.